Yanbing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanbing Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Weixing Wang
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China
2 shared publications - Chuiguo Huang
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
1 shared publication - Lei Zhu
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
1 shared publication Lilong Zhang
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China
1 shared publicationSi-Qi Yang
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University
1 shared publicationTianrui Kuang
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 13 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 956
Trends and Disparities in Cardiovascular Disease in US Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease
Background/Objectives: Recently, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). Through analysis of the trends and disparities regarding cardiovascular disease (CVD) among individuals with MASLD, identifying the leading cause of death in this population is crucial. Methods: We conducted a cross-sectional analysis of National Health and Nutrition Examination Survey (NHANES) III (1988–1994) and NHANES 2017–2020 data. MASLD was identified by using clinical profiles and liver ultrasonography to exclude other liver diseases. We estimated the prevalence of CVD among individuals with MASLD and calculated the prevalence ratios for those with and without MASLD. Results: In 2017–2020, MASLD affected 31.2% or 61.9 million US adults, and 17.0% (95% confidence interval: 13.7–20.3%) of these individuals had CVD. The absolute CVD prevalence in individuals with MASLD doubled from that in the NHANES III cohort, which was 8.7% (6.4%, 10.9%). These increases were especially notable among older adults, non-Hispanic whites, and those with higher education and income. Individuals with MASLD had a higher prevalence of total CVD than those without MASLD, even after adjusting for socioeconomic and metabolic factors. These differences were more pronounced in younger age groups. Conclusions: This study revealed a doubled 30-year trend in CVD prevalence among adults with MASLD in the US. Sociodemographic disparities emphasize the need for tailored screening, prevention, and policy measures to address gaps and promote cardiovascular health in this population.
- 13 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 956
Open AccessTrends and Disparities in Cardiovascular Disease in US Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease
Background/Objectives: Recently, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). Through analysis of the trends and disparities regarding cardiovascular disease (CVD) among individuals with MASLD, identifying the leading cause of death in this population is crucial. Methods: We conducted a cross-sectional analysis of National Health and Nutrition Examination Survey (NHANES) III (1988–1994) and NHANES 2017–2020 data. MASLD was identified by using clinical profiles and liver ultrasonography to exclude other liver diseases. We estimated the prevalence of CVD among individuals with MASLD and calculated the prevalence ratios for those with and without MASLD. Results: In 2017–2020, MASLD affected 31.2% or 61.9 million US adults, and 17.0% (95% confidence interval: 13.7–20.3%) of these individuals had CVD. The absolute CVD prevalence in individuals with MASLD doubled from that in the NHANES III cohort, which was 8.7% (6.4%, 10.9%). These increases were especially notable among older adults, non-Hispanic whites, and those with higher education and income. Individuals with MASLD had a higher prevalence of total CVD than those without MASLD, even after adjusting for socioeconomic and metabolic factors. These differences were more pronounced in younger age groups. Conclusions: This study revealed a doubled 30-year trend in CVD prevalence among adults with MASLD in the US. Sociodemographic disparities emphasize the need for tailored screening, prevention, and policy measures to address gaps and promote cardiovascular health in this population.
- Open Access
Mendelian randomization study on the association between cheese intake and diabetes
Objective To explore whether there is a causal relationship between cheese intake and diabetes through Mendel randomization (MR). Methods Two samples of MR were used to verify the causal effect of cheese intake on diabetes. The analysis was conducted using inverse variance weighted (IVW), weighted median, and MR-Egger regression methods. We used a meta-analysis of publicly available genome-wide association studies (GWAS) to compile statistical datasets, and cheese intake data as exposure factors were sourced from individuals of European ancestry in the UK biobank (n=451486). At the same time, GWAS’s public summary statistical data set is also used for self reporting non cancer disease codes: diabetes data included in the Finnish database (total n=184404; case=1219, control=183185) (http://www.finngen.fi/en)as a result. Result We selected 108 single nucleotide polymorphisms (SNPs) with genome-wide significance as instrumental variables from the GWAS intake of cheese. IVW method results show a causal relationship between cheese intake and diabetes (β=- 1.196, SE=0.3817, P=0.001729). MR Egger regression results show that directed pleiotropy is unlikely to bias the results (intercept=0.015; P=0.58), but there is no causal relationship between cheese intake and diabetes (β=- 2.073, SE=1.621, P=0.206). The results of weighted median method also showed that there was no causal relationship between cheese intake and diabetes (β=- 0.7828, SE=0.5701, P=0.1698). Cochran’s Q-test and funnel plot indicate no evidence of heterogeneity and asymmetry, indicating the absence of directed pleiotropy. Conclusion The results of MR analysis support that cheese intake may have a causal relationship with the reduced risk of diabetes.
Open AccessMendelian randomization study on the association between cheese intake and diabetes
Objective To explore whether there is a causal relationship between cheese intake and diabetes through Mendel randomization (MR). Methods Two samples of MR were used to verify the causal effect of cheese intake on diabetes. The analysis was conducted using inverse variance weighted (IVW), weighted median, and MR-Egger regression methods. We used a meta-analysis of publicly available genome-wide association studies (GWAS) to compile statistical datasets, and cheese intake data as exposure factors were sourced from individuals of European ancestry in the UK biobank (n=451486). At the same time, GWAS’s public summary statistical data set is also used for self reporting non cancer disease codes: diabetes data included in the Finnish database (total n=184404; case=1219, control=183185) (http://www.finngen.fi/en)as a result. Result We selected 108 single nucleotide polymorphisms (SNPs) with genome-wide significance as instrumental variables from the GWAS intake of cheese. IVW method results show a causal relationship between cheese intake and diabetes (β=- 1.196, SE=0.3817, P=0.001729). MR Egger regression results show that directed pleiotropy is unlikely to bias the results (intercept=0.015; P=0.58), but there is no causal relationship between cheese intake and diabetes (β=- 2.073, SE=1.621, P=0.206). The results of weighted median method also showed that there was no causal relationship between cheese intake and diabetes (β=- 0.7828, SE=0.5701, P=0.1698). Cochran’s Q-test and funnel plot indicate no evidence of heterogeneity and asymmetry, indicating the absence of directed pleiotropy. Conclusion The results of MR analysis support that cheese intake may have a causal relationship with the reduced risk of diabetes.
- Open Access
- 22 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1261202
Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy
Objective: The influence of body composition on the effectiveness of immune checkpoint inhibitors (ICIs) in patients with melanoma is still uncertain in clinical practice. Therefore, the objective of this study was to examine the potential association between body composition and clinical outcomes in patients with melanoma undergoing ICIs treatment.Methods: A systematic literature search was performed across several databases, including PubMed, Embase, Cochrane Library and Google Scholar, to gather relevant studies. The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS), assessed by hazard ratios (HR). Secondary outcomes, such as adverse events (AE), were evaluated using odds ratios (OR).Results: This meta-analysis comprised ten articles involving a total of 1,283 patients. Systemic analysis of all collected evidence revealed that body composition, including low skeletal muscle index (SMI) (OS: HR = 1.66, 95% CI = 1.13-2.43, p = 0.010; PFS: HR = 1.28, 95% CI = 1.06-1.55, p = 0.009), high subcutaneous adipose tissue density (SMD) (OS: HR = 1.93, 95% CI = 1.09-3.44, p = 0.025; PFS: HR = 1.31, 95% CI = 1.06-1.63, p = 0.012), and sarcopenia (OS: HR = 1.25, 95% CI = 1.03-1.51, p = 0.022; PFS: HR = 1.25, 95% CI = 1.03-1.51, p = 0.022), were significantly associated with OS and PFS in melanoma patients treated with ICIs. However, these markers did not show a significant association with treatment-related adverse events. Interestingly, no significant correlation was found between visceral fat index (VFI) (OS: HR = 0.71, 95% CI = 0.29-1.76, p = 0.462; PFS: HR = 0.98, 95% CI = 0.93-1.02, p = 0.274) and OS or PFS in melanoma patients under ICIs treatment.Conclusion: Body composition was found to be associated with decreased treatment response and lower long-term efficacy in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy. However, it is important to note that body composition did not appear to contribute to increased incidence of adverse events in these patients.
- 22 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1261202
Open AccessPrognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy
Objective: The influence of body composition on the effectiveness of immune checkpoint inhibitors (ICIs) in patients with melanoma is still uncertain in clinical practice. Therefore, the objective of this study was to examine the potential association between body composition and clinical outcomes in patients with melanoma undergoing ICIs treatment.Methods: A systematic literature search was performed across several databases, including PubMed, Embase, Cochrane Library and Google Scholar, to gather relevant studies. The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS), assessed by hazard ratios (HR). Secondary outcomes, such as adverse events (AE), were evaluated using odds ratios (OR).Results: This meta-analysis comprised ten articles involving a total of 1,283 patients. Systemic analysis of all collected evidence revealed that body composition, including low skeletal muscle index (SMI) (OS: HR = 1.66, 95% CI = 1.13-2.43, p = 0.010; PFS: HR = 1.28, 95% CI = 1.06-1.55, p = 0.009), high subcutaneous adipose tissue density (SMD) (OS: HR = 1.93, 95% CI = 1.09-3.44, p = 0.025; PFS: HR = 1.31, 95% CI = 1.06-1.63, p = 0.012), and sarcopenia (OS: HR = 1.25, 95% CI = 1.03-1.51, p = 0.022; PFS: HR = 1.25, 95% CI = 1.03-1.51, p = 0.022), were significantly associated with OS and PFS in melanoma patients treated with ICIs. However, these markers did not show a significant association with treatment-related adverse events. Interestingly, no significant correlation was found between visceral fat index (VFI) (OS: HR = 0.71, 95% CI = 0.29-1.76, p = 0.462; PFS: HR = 0.98, 95% CI = 0.93-1.02, p = 0.274) and OS or PFS in melanoma patients under ICIs treatment.Conclusion: Body composition was found to be associated with decreased treatment response and lower long-term efficacy in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy. However, it is important to note that body composition did not appear to contribute to increased incidence of adverse events in these patients.